Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 1,998 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at $1,156,782.30. The trade was a 6.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $42.00 on Thursday. The company’s fifty day moving average price is $42.86 and its 200-day moving average price is $40.61. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -20.79 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. The firm’s revenue was up 89.4% on a year-over-year basis. On average, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIRM. State Street Corp raised its stake in shares of Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Rice Hall James & Associates LLC lifted its stake in Mirum Pharmaceuticals by 6.9% in the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock worth $7,854,000 after purchasing an additional 14,843 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after buying an additional 17,149 shares during the period. Geode Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Mirum Pharmaceuticals by 48.2% in the second quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock worth $4,889,000 after buying an additional 46,506 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners increased their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.